These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19398376)

  • 1. Monitoring immunosuppression with measures of NFAT decreases cancer incidence.
    Giese T; Sommerer C; Zeier M; Meuer S
    Clin Immunol; 2009 Sep; 132(3):305-11. PubMed ID: 19398376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches towards individualized immune intervention.
    Giese T; Sommerer C; Zeier M; Meuer S
    Dig Dis; 2010; 28(1):45-50. PubMed ID: 20460889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
    Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
    Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
    Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
    Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
    Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
    Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
    Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
    Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients.
    Konstandin MH; Sommerer C; Doesch A; Zeier M; Meuer SC; Katus HA; Dengler TJ; Giese T
    Transpl Int; 2007 Dec; 20(12):1036-43. PubMed ID: 17850236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients.
    Billing H; Giese T; Sommerer C; Zeier M; Feneberg R; Meuer S; Tönshoff B
    Pediatr Transplant; 2010 Nov; 14(7):844-51. PubMed ID: 20602720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
    Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
    Trials; 2014 Dec; 15():489. PubMed ID: 25494823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants.
    Otley CC; Coldiron BM; Stasko T; Goldman GD
    Arch Dermatol; 2001 Apr; 137(4):459-63. PubMed ID: 11295926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous melanoma is related to immune suppression in kidney transplant recipients.
    Vajdic CM; van Leeuwen MT; Webster AC; McCredie MR; Stewart JH; Chapman JR; Amin J; McDonald SP; Grulich AE
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2297-303. PubMed ID: 19622722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin cancer and immunosuppression.
    Gerlini G; Romagnoli P; Pimpinelli N
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):127-36. PubMed ID: 15978830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Solid tumors after kidney transplantation].
    Moal MC
    Nephrol Ther; 2008 Oct; 4 Suppl 3():S214-7. PubMed ID: 19000890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell mediated immunity (CMI) and post transplant viral infections--role of a functional immune assay to titrate immunosuppression.
    Gautam A; Fischer SA; Yango AF; Gohh RY; Morrissey PE; Monaco AP
    Int Immunopharmacol; 2006 Dec; 6(13-14):2023-6. PubMed ID: 17161357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What's new in immunological monitoring?].
    Zuber J
    Nephrol Ther; 2008 Jun; 4 Suppl 1():S3-S7. PubMed ID: 18703396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks.
    Otley CC; Griffin MD; Charlton MR; Edwards BS; Neuburg M; Stasko T;
    Br J Dermatol; 2007 Dec; 157(6):1183-8. PubMed ID: 17916206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey.
    Otley CC; Berg D; Ulrich C; Stasko T; Murphy GM; Salasche SJ; Christenson LJ; Sengelmann R; Loss GE; Garces J;
    Br J Dermatol; 2006 Mar; 154(3):395-400. PubMed ID: 16445766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppression and other risk factors for lip cancer after kidney transplantation.
    van Leeuwen MT; Grulich AE; McDonald SP; McCredie MR; Amin J; Stewart JH; Webster AC; Chapman JR; Vajdic CM
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):561-9. PubMed ID: 19190169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New immunosuppressive strategies and the risk of infection.
    Mueller NJ
    Transpl Infect Dis; 2008 Dec; 10(6):379-84. PubMed ID: 18811628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.